Cane Capital Partners LLC Invests $1.38 Million in Johnson & Johnson $JNJ

Key Points

• Cane Capital Partners initiated a new Q4 position in Johnson & Johnson (JNJ), purchasing 6,687 shares worth about $1.38 million.
• Wall Street is broadly positive with a consensus rating of "Moderate Buy" and an average target of $238.17; several firms raised targets (e.g., Citi to $285, Wolfe to $240, Morgan Stanley to $267) though some analysts remain cautious.
• Insiders sold 30,142 shares (~$7.36 million) over the last quarter while institutional investors own roughly 69.55% of J&J and insiders hold just 0.16%.

Cane Capital Partners LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,687 shares of the company's stock, valued at approximately $1,384,000.

Several other institutional investors have also modified their holdings of JNJ. AustralianSuper Pty Ltd lifted its stake in Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company's stock valued at $16,536,000 after buying an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. lifted its stake in Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company's stock valued at $24,278,000 after buying an additional 2,769 shares in the last quarter. Guinness Asset Management LTD lifted its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company's stock valued at $251,216,000 after buying an additional 5,994 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock valued at $188,638,000 after buying an additional 94,957 shares in the last quarter. Finally, National Pension Service lifted its stake in Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company's stock valued at $913,484,000 after buying an additional 151,707 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Wolfe Research upped their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a research note on Monday, January 5th. Citigroup upped their target price on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday. Freedom Capital lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 16th. TD Cowen initiated coverage on Johnson & Johnson in a research note on Wednesday. They issued a "buy" rating and a $250.00 target price on the stock. Finally, Guggenheim boosted their price target on Johnson & Johnson from $240.00 to $244.00 and gave the company a "buy" rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $238.17.

Johnson & Johnson Trading Down 1.2%

Shares of JNJ opened at $238.34 on Friday. The stock has a fifty day moving average of $241.29 and a two-hundred day moving average of $214.99. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $574.06 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $146.12 and a fifty-two week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Morgan Stanley raised its price target to $267 and kept an "Overweight" rating, signaling roughly double-digit upside versus current levels and supporting buy-side interest. Read More.
• Positive Sentiment: Other broker notes (Guggenheim, Citi, and various upgrades) have recently pushed bullish research and helped intraday rallies. Read More.
• Positive Sentiment: Commercial/MedTech catalyst — J&J launched the VARIPULSE Pro pulsed field ablation system in Europe after CE mark approval, adding potential device revenue upside and real‑world evidence generation. Read More.
• Positive Sentiment: Dividend profile remains a tailwind for income investors — long streak of annual increases (>60 years) supports total‑return buyers. Read More.
• Neutral Sentiment: Fair‑value/target updates are moving modestly (consensus fair value around ~$241.7) — analysts are lifting some targets while flagging execution as the next focus, keeping valuation views mixed. Read More.
• Neutral Sentiment: Market is positioning for Q1 earnings — multiple previews and Wall Street estimate rundowns are circulating; that typically increases volatility into the print. Read More.
• Negative Sentiment: Some analysts and commentators are cautioning that this is “time to sell the rally” into Q1, arguing upside expectations may be priced in and that near‑term catalysts could disappoint. Read More.
• Negative Sentiment: Ongoing risks — litigation exposure, biosimilar competition and pricing pressure are repeatedly flagged as potential earnings/headwind items that could cap upside. Read More.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 22,623 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 over the last quarter. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.